Co-Trimoxazol-Sti

Co-trimoxazole-STI: a review of a combination antimicrobial agent

Co-trimoxazole-STI is a combined antimicrobial agent produced in Russia. It contains two active components - sulfamethoxazole and trimethoprim, which act synergistically, enhancing each other's effect and expanding the spectrum of activity.

Co-trimoxazole-STI is widely used in the treatment of infections of various origins, including respiratory tract infections, urinary tract infections, urogenital infections, gastrointestinal infections, infections of the skin and soft tissues, ENT organs, and also as a component of complex therapy for septicemia, meningitis, osteomyelitis and other severe infectious diseases.

Sulfamethoxazole and trimethoprim are folate metabolism inhibitors, interfering with the synthesis of deoxyribonucleic acid necessary for bacterial growth and division. In addition, co-trimoxazole-STI exhibits an additional antibacterial effect due to the synergy of the two components.

Co-trimoxazole-STI is produced by the company Sti-Med-Sorb in the form of tablets of 480 mg. It can cause side effects from the gastrointestinal tract, hematopoiesis, urinary system, allergic reactions and others. Co-trimoxazole-STI is contraindicated in cases of hypersensitivity to sulfonamides or trimethoprim, liver or kidney failure, B12-deficiency anemia, agranulocytosis, leukopenia, glucose-6-phosphate dehydrogenase deficiency, pregnancy, breastfeeding, childhood and hyperbilirubinemia in children.

Co-trimoxazole-STI is an effective and widely used antimicrobial agent, but its use should only be carried out as prescribed by a doctor, taking into account the individual characteristics of the patient and careful monitoring of possible side effects.